Health-care companies rose, but not by as much as the broad market, as traders rotated back into economically cyclical sectors.
Early laboratory studies suggest that a Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology is effective against the Omicron variant, the companies said, setting it apart from similar therapies that appear to work less well against the highly mutated strain.
Germany is tightening restrictions aimed at curbing the spread of the coronavirus amid a recent surge in cases, including a ban for unvaccinated people from retail and social gathering venues.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
12-02-21 1705ET
